Aeterna Zentaris Inc. (AEZS) Stock Price Down 2.8%
Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) were down 2.8% during mid-day trading on Wednesday . The company traded as low as $3.46 and last traded at $3.52, with a volume of 187,987 shares traded. The stock had previously closed at $3.62.
A number of analysts have recently issued reports on AEZS shares. Canaccord Genuity reissued a “buy” rating and issued a $9.00 price objective (down from $13.00) on shares of Aeterna Zentaris in a research note on Monday, April 4th. Maxim Group reissued a “buy” rating and issued a $11.00 price objective on shares of Aeterna Zentaris in a research note on Monday, May 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Aeterna Zentaris in a research note on Sunday.
The company’s market capitalization is $34.89 million. The firm’s 50-day moving average is $3.44 and its 200-day moving average is $3.49.
Aeterna Zentaris Inc is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development.